Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Apple Turns 50: From Garage Startup to AI Crossroads 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SALT LAKE CITY, Sept. 05, 2017 -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, being held September 11-13, 2017 at the Lotte New York Palace Hotel, in New York City.
| Presentation Details | ||
| Date: | Tuesday, September 12th | |
| Time: | 10:00 am Eastern Time | |
| Location: | Holmes I | |
| Webcast: | http://wsw.com/webcast/rrshq27/lpcn |
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes three development programs TLANDO, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.
CONTACT: Morgan Brown Executive Vice President & Chief Financial Officer Phone: (801) 994-7383 [email protected] Investors: Hans Vitzhum Phone: (646) 597-6979 [email protected]
